Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.
The availability of potent combination antiretroviral therapy has changed the long-term prognosis for people living with HIV/AIDS. There is increasing concern, however, about the effect of HIV therapy on lipid disorders and subsequent development of coronary artery disease. Virtually all classes of antiretroviral drugs have been associated with some aspect of atherogenic changes in the lipid profiles. This article reviews the current literature on HIV-associated dyslipidemias and the metabolic syndrome, their potential effect on future coronary heart disease, and reviews strategies for management.
Umeh
Obiamiwe C
OC
Center for AIDS Research and Education, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
Currier
Judith S
JS
D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D003327:Coronary Disease / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000209:etiology / Q000628:therapy; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000209:etiology* / Q000378:metabolism; D008875:Middle Aged; D012307:Risk Factors; D014481:United States / Q000453:epidemiology